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Abstract: Gene network estimation is a method key to understanding a fundamental cellular
system from high throughput omics data. However, the existing gene network analysis relies on
having a sufficient number of samples and is required to handle a huge number of nodes and
estimated edges, which remain difficult to interpret, especially in discovering the clinically relevant
portions of the network. Here, we propose a novel method to extract a biomedically significant
subnetwork using a Bayesian network, a type of unsupervised machine learning method that can
be used as an explainable and interpretable artificial intelligence algorithm. Our method quantifies
sample specific networks using our proposed Edge Contribution value (ECv) based on the estimated
system, which realizes condition-specific subnetwork extraction using a limited number of samples.
We applied this method to the Epithelial-Mesenchymal Transition (EMT) data set that is related to the
process of metastasis and thus prognosis in cancer biology. We established our method-driven EMT
network representing putative gene interactions. Furthermore, we found that the sample-specific
ECv patterns of this EMT network can characterize the survival of lung cancer patients. These results
show that our method unveils the explainable network differences in biological and clinical features
through artificial intelligence technology.
Keywords: gene network; differential network analysis; lung cancer survival analysis; EMT
1. Introduction
The use of high throughput technologies in molecular biology has led to the generation of large
volumes of data, and thus, the development of precise methods for handling such large data is required.
Understanding the cellular mechanisms at a system level forms a fundamental goal of these methods.
Elucidation of the cellular mechanisms is indispensable for discovering biologically significant events,
especially for clinical applications like finding new drug targets [1].
Researchers have developed several approaches to elucidate cellular mechanisms. One of the most
popular methods is the conventional mRNA expression analysis to identify Differentially Expressed
Genes (DEG) [2,3]. This method extracts independent genes using differences of expression levels
between different conditions; e.g., control and perturbated samples. Likewise, pathway analysis maps
genes onto known pathways to classify genes based on their enrichment in the maps of well-known
pathways, such as the EGFR signaling and DNA damage repair pathways [4–6]. These traditional
approaches, however, are unable to discover de novo pathways and relationships.
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Network analysis constitutes a promising method to interpret the big omics data, and researchers
have applied it to many biomolecular investigations [7,8]. However, since the gene network estimation
brings in a huge number of putative gene regulatory relationships often expressed as a hairball [9],
establishing a method for identifying biologically significant subnetworks or inter-gene relationships
from such a large and complicated network has been challenging. Established methods that identify
regulatory relationships in large gene networks mainly adopt two approaches: one focuses on hub
genes that have a large number of connections [10–13], whereas the other, known as differential
network analysis [14], compares network structures derived from different conditions. While the
former approach fails to extract edges regardless of the gene network analysis, the latter requires
individual networks reflecting different conditions. Nonetheless, it remains difficult to satisfy sufficient
sampling to generate data-driven and condition-dependent networks. For instance, our study uses
a data set that consists of only three samples per condition, which makes a Bayesian Network (BN)
and structure-based approach unfeasible.
Herein, we propose a novel method to extract a biomedically differentiated subnetwork from
a huge number of edges in a gene network estimated using a relatively small number of samples.
Compared to the structure-based network analysis, our approach aims to extract edges, which represent
the system-level differences between the samples in cellular networks without comparing network
structures. Therefore, even with a limited number of samples for conditions of interest, our method
will extract system-based differential networks. The outline of the proposed method is shown in
Figure 1. Following the reported method [15], a gene network from the available gene expression
data sets was estimated using nonparametric BN. This generates a basal network with more than
a hundred thousand edges between approximately 20,000 genes. Most importantly, our method
calculates an Edge Contribution value (ECv) for every single edge in a gene network with respect to each
sample. The proposed ECv can quantify a particular edge for each sample using the estimated model.
Therefore, based on the differences in ECvs between different samples, which imitate biologically or
clinically-specific phenomena, our method highlights the differentiated subnetwork. This method
defines the edges out of a possible hundred thousand links between genes, and thus demonstrates
major differences in regulating the basal gene network potentially associated with target diseases
or phenomena. Since the extracted subnetwork highlights specific differences between samples,
it may portray expression data sets that are not used in network estimation or subnetwork extraction.
We proved that the network ECv pattern with respect to a patient sample for certain types of diseases
can be adopted for clinical classifications by validating real data.
The idea of estimating sample specific gene networks has already been addressed. For instance,
Shimamura et al. (2011) [16] proposed a structural equation-based model that estimated sample specific
regulator-modulator-target relationships. Their method assumes the gradual effect of modulators to
parent-child relationships throughout the collected samples. Thus, this method generally requires
sufficient samples to detect such relationships. Yu et al. (2015) [17] tried to extract personalized
gene networks based on their differential network model. Their model assumes an existing network,
such as the protein-protein interaction network, and combines it with genes extracted by traditional
methods such as DEG and gene pairs that are independently evaluated by their novel differential
expression covariance method on that network. Kuijjer et al. (2019) [18] proposed a method to estimate
sample-specific regulatory networks where the linear combination of edge weights in particular
networks forms the aggregated network. Unlike these existing methods, our proposed method
estimates a globally optimized structure as a cellular model with the BN model and correlates edge
differences to the samples using the estimated model parameters. None of the existing methods realize
extraction of the edge from a limited number of samples and a large network except for our method.
We examined our method on Epithelial-Mesenchymal Transition (EMT) [19] to understand its
process through the representative EMT subnetwork; we then applied it to The Cancer Genome
Atlas project (TCGA) clinical data [20]. In this analysis, the basal network was estimated from the
small number of samples mimicking EMT in lung cancer cell lines. By comparing ECvs between
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EMT-induced and control samples, we succeeded in extracting the EMT-characterized network.
In addition, we applied this EMT network to TCGA clinical data to test if the network can generate
a prognosis profile, as EMT is a major factor involved in the prognosis of cancer patients. Our results
show that the prognosis for lung cancer patients was partially associated with the ECv patterns in the
EMT network, according to the survival analysis. This indicates that our proposed method correctly
extracts a subnetwork determining patients’ EMT characteristics from a large number of nodes and
edges in the network.
The EMT network by ΔECv
Basal gene network
19,849 genes  18 samples
150 genes  411 edges
(incl. 120 selected edges)
Gene network estimation
by the NNSR algorithm
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by the EMT network
Figure 1. Overview of our proposed method. The center hairball (blue) is the basal network.
The red nodes in the basal network represent the ∆Edge Contribution value (ECv)-extracted
Epithelial-Mesenchymal Transition (EMT) network.
2. Materials and Methods
2.1. Nonparametric Bayesian Network
As described in the Introduction, we used nonparametric BN to estimate a gene-to-gene regulatory
system from gene expression data [21]. The BN estimation is an unsupervised machine learning
algorithm that is able to capture cause-and-effect relationships among variables from its observations
by optimizing the global structure of the network. Therefore, it constitutes an ideal method to estimate
gene regulatory systems and has been successfully applied to many gene network analyses [12,22,23].
In this section, we provide a brief explanation of the model.
Let X be an n-by-p data matrix whose element xij corresponds to the observation of the j-th
variable; that is, the expression value of the j-th gene, at the i-th sample, where n represents the total
number of samples and p the number of variables. In the nonparametric BN model, we consider the
joint density of all the variables and assume that it can be decomposed as the product of the local
conditional densities, such as
Biomolecules 2020, 10, 306 4 of 17




f (xij|paGij (xij); θj), (1)
where paGij (xij) = (pa
(j)
i1 , . . . , pa
(j)
iqj
) is the set of observations in the i-th sample of qj dependent
variables of the j-th variable, and θG = (θ1, . . . , θp) are the parameters of the conditional densities.
This decomposition can be represented by a directed acyclic graph consisting of nodes representing
variables and edges connecting the nodes called “children,” to their dependent variables called
“parents.” To model parent-child relationships, we employ B-spline nonparametric regression. In the










) + ε j, (2)








ik ) for 1 ≤ k ≤ qj and ε j ∼ N(0, σj). Here, b
(j)
lk (·) is a third-order
B-spline function which is determined by the range of the observations and γ(j)lk is its coefficient. M is
the number of the B-splines and we use M = 20 as used in Imoto et al. (2002) [21]. The local density in
Equation (1) can be written as




−{xij −∑qjk=1 ∑Ml=1 γ(j)lk b(j)lk (pa(j)ik )}2
2σ2j
 ,
where θj = (γ
(j)
1,1, . . . ,γ
(j)
M,qj
, σ2j ) is the parameter vector for the local density to be estimated from






f (xi1, . . . , xip; θG)pi(θG|λ)dθG,
where G represents the network structure, pi(G) the prior probability of G and pi(θG|λ) the prior
distribution of θG. Here λ is the hyperparameter vector determined also by the maximization of the
posterior. Searching for the optimal structure of the BN is known to be an NP-hard problem. Thus,
we use the Neighbor Node Sampling and Repeat (NNSR) algorithm [15] that is applicable to more
than twenty thousand genes for obtaining an approximated structure of the huge BN. We call this
network the basal network in the later steps.
2.2. Proposed Method for Evaluating Sample Specific Edge Contribution Values
Our basic idea is to evaluate a single edge value of an observed sample through the mathematical
model estimated as a BN. In the model, the expression value of a child gene is represented by a linear
combination of their parent values transformed by the functions denoted as m(j)k (·) in Equation (2).
Considering this nonparametric regression function, m(j)k (pa
(j)
ik ) can be regarded as a contribution
of the k-th parent of the j-th gene to the expression value of xij, because these values of qj parents
constitute the value of their child. According to this, we define Edge Contribution value (ECv) of edge
jk → j with respect to the i-th sample as
ECv(i)(jk → j) = m(j)k (pa
(j)
ik ),
where jk represents the index of the k-th parent of the j-th gene.
Since ECv is calculated from the model parameters to every single edge in the estimated network,
the ECv of an edge can be considered as its edge weight, representing how it contributes to the link
between a node pair for a certain sample. However, this calculation of ECv alone does not represent
an evaluation of the absolute importance of the edge, because it is impossible to determine the size of
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calculated ECv. This is similar to gene expression values where differential expression is considered.
Therefore, two ECvs of an edge must be compared between samples. For instance, let us assume that
there are control and drug-perturbated samples in an in vitro cell assay. To obtain the differential edge
in terms of ECv, we define a variation of ECv, ∆ECv, as
∆ECv(jk → j) =
∣∣∣∣∣ 1|S| ∑s∈S ECv(s)(jk → j)− 1|T| ∑t∈T ECv(t)(jk → j)
∣∣∣∣∣ ,
where S and T are sets of indices of samples observed in particular conditions, respectively.
The graphical representation of ∆ECv is shown in Figure 2.
The ∆ECv of an edge is the absolute difference that stands for the difference in edge contribution
between samples of different conditions. Thus, an edge that shows significant ECv difference between
certain samples represents a distinctive edge. In our experiment, ∆ECv implementation did not result
in a large number of candidate edges that were needed for following the investigation. This suggests
that ∆ECv functions as a screening method for candidate networks from the estimated basal networks
that are important under certain conditions. The network estimation with a small number of samples
generally increases the number of false positive edges due to spurious correlations between variables.
It is expected that the ∆ECv can overcome this problem, because ∆ECv might highlight a sample
difference which is determined by not only the estimated model but also the sample-specific differences
through the estimated model. Note that the number of samples in S and T here can be 1 because we
focus only on differences of ECv so that only a single pair of samples is required to extract edges.
As a consequence of ECv calculation, we obtain a matrix consisting of ECvs for all of the edges
and samples. We call this ECv matrix. More precisely, the ECv matrix E is an n-by-m matrix whose
element eiv corresponds to ECv of the v-th edge at the i-th sample, where m represents the total number
of estimated edges and n the number of samples. The ECv matrix thus can be considered as a set of
each sample’s ECvs. Since ECv originally represents the sample-specific profiling for each estimated
edge, clustering of the ECv matrix highlights differences according to ECvs for each sample, which
then allows for the grouping of samples based on their system-level similarities.
X Y









Figure 2. Graphical representation of ∆ECv. Line (blue) is a nonparametric regression curve m(Y)1 (X)
for edge X → Y estimated with Bayesian Network. Plots for X axis correspond to actual mRNA
signal values and Y′ axis partial residuals where the effects of the other parents are subtracted from
the children’s mRNA signal values. Plots (green) and plots (yellow) represent, for instance, control
and perturbated samples, respectively. Plots (grey) represent other values used for determining the
regression curve. Values in Y′ axis also stand for output through the regression function with parents’
mRNA signals. By the definition, these correspond to ECvs. ∆ECv is defined as the difference between
two conditions. In this example, the difference of ECvs between perturbated and control samples,
i.e., the ∆ECv of these two conditions, is depicted.
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2.3. Data Preparation
The microarray data for EMT analysis were acquired from Gene Expression Omnibus
(GSE49644) [19]. The data set is composed of three human Non-Small Cell Lung Cancer (NSCLC)
cell lines: A549, HCC827 and NCI-H358. The microarray experiments were replicated 3 times for
both control and TGFβ-treated cells. Thus, the data consists of 3× 3× 2 = 18 samples in total and
19,849 genes. The log2-transformed values of preprocessed data were applied to BN estimation and
ECv calculation. The clinical and RNA-seq data of lung cancer patients [20] were acquired from the
Genomic Data Commons Data Portal at TCGA and UCSC Xena [24]. NSCLC patients with either Lung
Squamous Cell Carcinoma (LUSC) or Lung Adenocarcinoma (LUAD) were selected. The patients were
first screened to obtain tumor specimens. RNA-seq data was filtered to remove genes with a mean
percentile lower than 15, resulting in 17,450 genes. In the clinical data, we removed entries for patients
whose follow-up or decease data was more than 2000 days. Further to these preprocesses, we deleted
the patient data that were not common in the RNA-seq and clinical data. The number of the final
patients for analyses was 426 (alive: 238, deceased: 188) for LUSC and 457 (alive: 285, deceased: 172)
for LUAD. The details of the acquired data above are listed in Table S2.
2.4. Differential Expression Gene Analysis
The differential expression gene analysis for GSE49644 microarray data was performed using
R package limma [25]. Benjamini-Hochberg method was applied for calculation of False Discovery
Rate [26].
2.5. Molecular Function Analysis
The functional analysis was generated through the use of Ingenuity Pathway Analysis [27].
2.6. ECv Matrix Clustering and Survival Analysis
Unsupervised-clustering for the ECv matrix was performed using the “ward.D2” clustering
method with Euclidean distance for both edges and samples in R. The following survival analysis was
performed with log-rank test using R package surveminer and TCGAbiolinks [28,29].
2.7. Network Analysis and Visualization
The network visualization and a part of network analysis were performed using Cytoscape [30].
2.8. Computation Environment
All the computation for the network estimation and the ECv calculations in this study were
performed by the SHIROKANE supercomputer system (Shirokane3) at Human Genome Center, the
Institute of Medical Science, the University of Tokyo, where the computation nodes were equipped
with dual Intel Xeon E5-2670 v3 2.3GHz CPUs and 128GB memory per node.
3. Results
3.1. Basal Gene Network Estimation
For the basal gene network estimation using the BN, we adopted the NNSR algorithm [15] as
described in Materials and Methods. The algorithm repeatedly iterates subnetwork estimations in
parallel many times for gene sets extracted by the neighbor node sampling method, and determines
a final network structure by incorporating edges whose estimated frequencies are greater than the
cutoff threshold. The frequencies correspond to strengths of edges in terms of stability or confidence of
them. To begin with, we tuned these parameter settings for our analysis. As for the cutoff threshold,
since the number of extracted edges was fixed with another quantitative measurement after the network
estimation, we employed a threshold of 0.1, which is slightly relaxed comparing the default setting
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(threshold of 0.2), to include weak putative edges in this step. Although the algorithm can estimate
networks for more than ten thousand genes, it supposedly requires more than a hundred samples for
an input data. Therefore, we needed to confirm if the algorithm would work with an extremely small
number of samples; i.e., 18 samples in our case. For this purpose, we defined the degree of concordance
between two networks as the ratio of edges that are estimated in both networks to the total number of
edges, and then we tested whether the algorithm produced stable results using this degree. Following
the recommendations of Tamada et al. (2011) [15], we performed the network estimation three times
with 10,000 times as the number of iterations (we denote this as “T”) of the subnetwork estimation,
and calculated the averaged degree of concordance for every estimated-network pair. As a result,
the degree of concordance was 72.7%, suggesting that the algorithm could not produce stable gene
network structures (Table 1). Therefore, we assessed whether the increased T resulted in stable network
structures with the EMT data set. We performed identical evaluations as above for T = 100,000, 500,000
and 1,000,000. We found that T = 1,000,000 was sufficient for our network analysis owing to reduced
error rate below 5% and the stable networks with just 18 samples. The results are summarized in
Table 1. The final network structure consisted of 154,369 edges with a threshold of 0.1 (Table S1) and
the node degree average of 15.55. This basal network is shown in Figure 1. When we used our data set
consisting of 19,849 genes and 18 samples, the computation time required for this network estimation
was 7 h 55 m 42 s at T = 1,000,000 using 64 CPU cores.






3.2. ∆ECv Highlights the EMT-Characterized Edges
To examine if our proposed method is applicable to real data, we applied an ECv calculation
to the basal network. The microarray data cells were treated with TGFβ to induce EMT. EMT is
a cellular process in which metastasis and invasion are involved [31]. Although EMT has been
well-investigated and many EMT-related genes were identified, its molecular mechanism is not fully
understood. Once cancer cells invade tissues, this is critical for treatment of cancer and even more
so for patient prognosis. Therefore, we aimed to extract an EMT-characterized subnetwork which
represents a putative core mechanism of EMT as a cellular system modeled by the nonparametric
regression. Compared to control cells, TGFβ-treated cells represented the EMT profile, which was
confirmed by the alteration in cellular morphology and expression levels of EMT markers in the
previous study [19]. Following ECv calculation, a 18-by-154,369 ECv matrix was obtained. Since the
samples were replicated three times for both control and EMT-induced conditions over three cell lines,
we calculated ∆ECv with respect to each cell line as
∆ECv(u)(jk → j) =
∣∣∣∣∣∣13 ∑s∈{EMT-induced} ECv(u)(s) (jk → j)− 13 ∑t∈{control} ECv(u)(t) (jk → j)
∣∣∣∣∣∣ ,
where u = A549, HCC827 and NCI-H358. The edges that were assigned high ∆ECv can be considered
as significant differences in the cellular system between control and EMT-induced samples in each
cell line. The distribution of ∆ECv values for each cell line is displayed in Figure 3A. As shown, most
edges do not show significant differences between the two conditions. The number of edges with
∆ECv more than 1.0 for A549, HCC827 and NCI-H358 were only 946, 1420 and 1041, respectively,
out of 154,369. Given that the total number of edges in the estimated network is 154,369, ∆ECv
filters out edges which are assumed to be significantly different in EMT. To compare the log2 Fold
Change (FC) distribution of mRNAs, which is a standard indicator in DEGs, we overlapped their
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histograms (Figure 3A). This showed that the distribution of ∆ECv is much steeper than that of log2FC
throughout the thresholds, suggesting that ∆ECv can be considered as a better indicator for extracting
condition-dependent edges. We set ∆ECv threshold as 1.0 because it corresponds to approximately top
0.1% of edges out of the total number of edges. To gain reliable EMT-distinctive edges, we extracted
120 edges which exceeded the threshold in all of the three cell lines that are composed of 150 genes
(Figure 3B,C). Because there were nine samples both for TGFβ-treated and control cells, we can evaluate
statistical significance of the extracted edges. We performed t-tests for ECv between TGFβ-treated and
control samples, and found that 108 edges out of ∆ECv-extracted 120 satisfied the criteria of FDR (False
Discovery Rate)-corrected p value < 0.01 (Figure S1). This supports that ∆ECv extracted edges are
statistically significant, even though we estimated the basal network from a small number of samples.
Furthermore, considering that we used log2-transformed expression data, threshold 1.0 for ∆ECv was
generally supposed to be a 2-FC cutoff for the estimated system. Therefore, we hypothesized that 1.0
was a moderate threshold for the EMT data set and used this in the following analyses. The ∆ECv heat
map reflects the samples’ distinctive ECv matrix for the selected 120 edges (Figure 3D). This shows
that the EMT-induced and control samples were clearly separated into two clusters, which further
suggests that our ECv method captures the EMT-induced pattern of cellular network differences.
3.3. ∆ECv Unveils the EMT Networks
Using these ∆ECv-extracted edges, we aimed to build and visualize a network. We mapped
120 edges and linked the edges that are absent in ∆ECv using their connections in the basal network,
resulting in the establishment of the EMT-characterized subnetwork (hereafter referred as the EMT
network) (Figure 4). Eventually, this network comprised 150 nodes and 411 edges. Remarkably, the
EMT network shared many nodes of ∆ECv-extracted edges; i.e., these edges were linked to each
other. The biggest connected component in the 120 ∆ECv-extracted edges consisted of 54 edges with
50 nodes. Many other connected components or independent edges were also connected to the biggest
one within a single edge of the basal network, whereas only few edges were completely isolated.
The inclusion of the basal network edges resulted in the connected component consisting of 371 edges
with 127 nodes in the EMT network. Additionally, if we highlighted the ∆ECv-extracted nodes and
edges in the basal network whose node layout was arranged only using its topological structure,
we observed that those were closely located and seemed to constitute a module in the basal network
(Figure 1). Furthermore, we mapped top 5% rank hub genes for the basal network and the EMT
network to compare their topological localizations in the EMT network and identified 28 of the 1156
genes as the ECv-extracted genes (Figure 4). Interestingly, these basal hub genes did not function as
hub genes in the EMT network.





















A549 A549NCI-H358 NCI-H358HCC827 HCC827
EMT-induced control
Figure 3. ∆ECv analysis. (A) The histograms of absolute ∆ECv (green) and absolute log2 Fold Change
(FC) (magenta) for each cell line. FC is defined as TGFβ-treated/control. The number of total edges
is 154,369 for ∆ECv. The total number of genes for log2FC is 19,849. Y axis stands for density. X axis
corresponds to the threshold for each ∆ECv and log2FC. (B) The Venn diagram represents the numbers
of ∆ECv-extracted edges for all the cell lines with threshold 1.0. (C) The subnetwork of all the 2601
edges which were extracted from each cell lines by ∆ECv. The nodes (150) and edges (120) with red
highlight the common edges for each cell line. (D) Heat map and the result of hierarchical clustering
for the ECv matrix of ∆ECv-extracted 120 edges with 18 samples.
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Figure 4. Visualization of the EMT network. One hundred and fifty nodes and 411 edges constitute
the network. The total number of connected components is seven. Node: The top 5% hub genes
(filled with red) in the EMT network, and the top 5% (labeled with red) hub genes in the basal network
are displayed. Nodes (blue line) represent genes extracted by ∆ECv exclusively. Edge: Bold edges
(grey) and standard edges (grey) represent ones with absolute ∆ECv more than 1.5 and 1.0, respectively.
ECv high 38 (green) and low (magenta) 70 edges in TCGA data-fitting experiment (Figure 6A and
Figure S3B) are labeled. Dotted edges (grey) originally belonged to the basal network.
3.4. Biological Validation for the EMT Network with the Comparison between ∆ECv and DEG
To investigate the extent to which ∆ECv-extracted genes explain the EMT features biologically,
we conducted a method-based comparison between ∆ECv and DEG. The DEG analysis was performed
by a criteria of absolute log2FC > 2 and FDR-corrected p value < 0.00001, approximately following
a previous report [19], resulting in 125 genes (Figure S2). This DEG-extracted gene set principally
reflects a difference between control and TGFβ-treated samples. The number of shared genes
obtained by ∆ECv and DEG was 71 (Figure 5A), suggesting that some population of the ∆ECv
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genes belongs to the DEG-extracted gene set. Considering that 2-FC is a standard lowest cutoff for
making a decision for potential DEGs, the remaining 79 genes for ∆ECv and 54 genes for DEG might
be exclusive for each method (Figure 5A). This implies that network-driven ∆ECv can extract genes
that the conventional DEG method never does. To get more of an insight into the biology involved,
we examined whether biological functions are different between the gene sets obtained by these two
methods. The molecular functions in the top 6 ranks out of 10 are exactly the same between them
(Figure 5B,C), and the top 3 functions of “cellular movement,” “cellular development” and “cellular
growth and proliferation” might represent the EMT features. This further supports that at least the
major population of ∆ECv-extracted genes consists of EMT-related genes. Moreover, we observed that
representative EMT markers, CDH1 and CDH2, were included in the EMT network (Figure 4). These
results show that our method enables us to identify genes that are not identified through DEG, along
with a biological validity, indicating the advantage of our ∆ECv method.
3.5. A Clinical Approach Using the EMT Network
Finally, considering that ∆ECv enables us to emphasize network differences between normal and
clinically relevant samples, we attempted to investigate whether the pattern of ∆ECv-extracted edges
over patients’ samples identifies their properties regarding their EMT network suitability. We directly
applied the EMT network on the RNA-seq data of the two types of lung cancer (LUSC and LUAD)
patients by calculating their own RNA-seq specific ECv as
ECv′(i)(jk → j) = m(j)k (pa
′(j)
ik )
where pa′(j)ik represents the RNA-seq expression of the k-th parent of the j-th node in the basal
network, and i the patient index in the TCGA data set. Note that m(j)k (·) here is the same as the
one estimated for the 18-sample microarray data, and we calculated them for only the ∆ECv-extracted
edges. This experiment tried to reassign the EMT network, which was obtained by the microarray
data, to a new RNA-seq data. We hypothesized that it can also highlight the EMT network in the
RNA-seq data. Due to the differences in the total number of genes between the microarray and
RNA-seq data, we performed this on the 136 genes shared with both EMT network and RNA-seq to
gain an RNA-seq-derived ECv, resulting in 108 edges out of 120 edges. Therefore, this ECv calculation
produces the 426-by-108 and 457-by-108 ECv matrix for both LUSC and LUAD. The ECv patterns
of these matrices were shown as a heat map along with the result of the unsupervised clustering
analysis (Figure 6A and Figure S3A). The 108 edges were classified into ECv high and low clusters,
indicating that these are involved in network gene up or down-regulation. Since the patients were
clearly clustered into two groups, we considered that these groups highlight a system difference in the
process of EMT. Given that the metastasis and invasion that is a consequence of EMT is fatal for patients’
cancer prognosis, in order to ask whether these two groups are clinically different, we performed
a survival analysis. The result showed that, although this failed (log-rank test p = 0.1) for LUAD
(Figure S3B), these two groups were significantly different (p = 0.011 < 0.05) in terms of their prognosis
for LUSC (Figure 6B), suggesting that the LUSC patients were distinguished into groups of better and
worse prognosis by their ECv patterns based on their EMT network differences.








Figure 5. Comparison of ∆ECv and Differentially Expressed Genes (DEG). (A) Venn diagram for
the genes extracted by ∆ECv and DEG. (B) Top 10 terms of the molecular function analysis for the
∆ECv-extracted 150 genes. (C) Top 10 terms of the molecular function analysis for the 125 genes
through DEG.
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Figure 6. Unsupervised clustering and survival analysis for Lung Squamous Cell Carcinoma (LUSC).
(A) Heat map with hierarchical clustering for the ECv matrix of 108 edges with 426 samples in LUSC
RNA-Seq data. (B) Kaplan-Meier curves for the two patient groups; group 1 (blue, n: 244) and group 2
(orange, n: 182), corresponding the patient clusters in the heat map in A. The survival analysis was
performed using log-rank test for p value calculation.
4. Discussion
Here, we report a novel method to obtain a sample-specific subnetwork using ECv derived from
the estimated parameters of the BN. We investigated the application of this method in EMT biology
and clinical data analysis. Our method shows the potential ability of capturing the subnetwork and the
patient-specific ECv patterns, and these patterns further characterized the prognosis. The prognosis in
cancer patients depends on more than the metastasis. This is probably one reason why the combination
of clustering and survival analysis works on LUSC, but not LUAD. On the other hand, the results of
conventional clustering analysis on ECv matrices showed clear discriminations into two groups both
on cell line microarray data and patient tumor sample RNA-seq data. Therefore, our results imply that
individuals are distinguished through network differentiation using the proposed quantification of
the edges.
Although translating laboratory experiments into the clinical context remains a big hurdle, this
study indicates that our approach could be a powerful tool for bridging the divide between them.
However, if we use it for this purpose, in vitro experimental design should at least relate directly
to practical clinical realities. In addition, because some data sets in replicate experiments involving
in vitro assays are markedly homogeneous, we calculate ∆ECv using mean ECv difference for each
condition-specific sample set in this study. This, however, would not be appropriate for a heterogeneous
data set because mean ECv is not supposed to reflect a representative ECv for a particular set of samples.
These issues are current limitations of our proposed method and can be improved in the future work.
As discussed previously, existing gene network analyses generally focus on hub genes that are
supposed to catalog important regulatory genes in a network. In the EMT network, most of the basal
network hub genes were either located at the corners of the EMT network or completely isolated
from the biggest connected component (Figure 4). Only a few of these hubs are at the network’s
center, suggesting that the basal network hub genes are the master regulators responsible for various
cellular processes in the basal network, but not in specific functional modules in the EMT network,
as discussed below. This may imply that the major difficulty in hub gene analysis lies in the acquisition
of significant genes, especially for samples relating to specific conditions. However, this may also
suggest that the network estimation involves appropriate consideration of all the system-level cellular
features, even when the number of samples are very small and are measured for a specific condition.
Within the biggest connected components in Figure 4, HS3ST3B1, FAM198B and IGFBP5 are
the three top hub genes of the EMT network. Genes farthest from the hub genes were closely
linked, suggesting that the subnetwork centered on the hub genes essentially represents EMT
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profiles depicted in the EMT data set. In particular, we found that these components are more
enriched in Extracellular Matrix (ECM) genes. ECM constructs a multilayer scaffold structure
located outside of the cell membrane and functions as an attachment between cells and tissues,
assisting in cell growth, movement, development and differentiation [32]. Given that collagen,
proteoglycan and Glycosaminoglycans (GAGs) constitute ECM, it is reasonable that ECM-functional
genes, HAS3, FN1 and MMP7 are located proximally to the top three hub genes. HS3ST3B1 encodes
an enzyme that controls the ECM environment following organization of heparin sulfate in GAGs,
and reports show its expression level regulates EMT [33]. A low level of FAM198B attenuates tumor
growth and metastasis [34]. Overexpression of IGFBP5 reduces EMT [35]. Although these reports
support the notion that hub genes identified in our study actually engage in the EMT process,
elucidation of the EMT mechanism remained incomplete, as clear interactions have not been defined.
Given that dysregulation of ECM was found to be a profound connection with EMT [36], our EMT
network indicates a possible regulatory system of interactions between ECM and EMT. Moreover,
PDK4—identified biologically as a novel EMT-associated gene [19]—has a network location close to
the hub genes, supporting our finding of including this previously validated gene and the interaction
of PDK4 with EMT-related genes.
Recently, the emergence of deep learning technology has allowed us to apply it to many scientific
fields, including biology and medicine. However, such a situation depends on a large number
of data sets. More importantly, the explainability of deep learning technology remains elusive.
This disadvantage is a key issue, especially for biological or clinical situations, because the predictive
process must also have a responsibility for interpretation and the ultimate outcome. In contrast, BN
has been conventionally developed as an explainable model, and thus it is considered to be more
appropriate to these fields. However, BN was unable to explain the individuality of samples and
additional statistical models intended to interpret the population of certain data sets. In this study, by
overcoming this weakness of BN, ECv has proven to be a more powerful tool in terms of explainability
in machine learning. Therefore, the application possibilities of this BN model regarding biomedical
data beyond existing bioinformatics methods makes it superior to other models. Although multi-omics
analysis is becoming mainstream in biology, single transcriptome analysis still possesses a broad
scope. Integration of other types of omics data, such as genome, proteome and epigenome data, with
transcriptome data using BN, would lead us to analyze these big data sets more precisely than in
existing studies, which in turn may result in a new approach in precision medicine.
5. Patents
Y.T. (Yoshinori Tamada) and Y.O. have a patent application on the individual profiling and sample
specific network extraction method, and its applications used in the submitted study through the
technology licensing organization in Kyoto University.
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Abbreviations
The following abbreviations and mathematical notations are used in this manuscript:
ECv Edge Contribution value
EMT Epithelial-Mesenchymal Transition
BN Bayesian Network
DEG Differentially Expressed Gene
TCGA The Cancer Genome Atlas project
NNSR the Neighbor Node Sampling and Repeat algorithm
NSCLC Non-Small Cell Lung Cancer
LUAD Lung Adenocarcinoma
LUSC Lung Squamous Cell Carcinoma
X n-by-p data matrix whose element xij corresponds to the expression value of the j-th gene at
the i-th sample (samples: 1 ≤ i ≤ n, genes: 1 ≤ j ≤ p)
pa(j)ik expression value of the k-th parent of the j-th gene at the i-th sample
θ parameter vector of the conditional density
m(j)k (pa
(j)
ik ) value of the regression curve by B-splines, or contribution of the k-th parent of the j-th gene to
the expression value of xij
σj standard deviation for total observations of the j-th gene
ECv(i)(jk → j) edge contribution value for edge jk → j with respect to the i-th sample
E n-by-m ECv matrix whose element eiv corresponds to ECv of the v-th edge at the i-th sample
(samples: 1 ≤ i ≤ n, edges: 1 ≤ v ≤ m)
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